Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C

Background. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5‐fluorouracil (5‐FU) and mitomycin‐C infusion in inoperable head and neck cancer. Methods. Seventy‐six patients (86% men, 14% women), mean age 57 years, with primary inoperable head and n...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2004-10, Vol.26 (10), p.845-853
Main Authors: Christiansen, Hans, Hermann, Robert M., Hille, Andrea, Weiss, Elisabeth, Nitsche, Mirko, Martin, Alexios, Hess, Clemens F., Pradier, Olivier
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic - therapeutic use
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy, Adjuvant
Female
Fluorouracil - therapeutic use
Follow-Up Studies
head and neck cancer
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - mortality
Head and Neck Neoplasms - radiotherapy
hemoglobin
Hemoglobins - analysis
Humans
Male
Medical sciences
Middle Aged
Mitomycin - therapeutic use
mitomycin-C
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Prognosis
prognostic factors
radiochemotherapy
Radiotherapy, Adjuvant
Remission Induction
Retrospective Studies
Survival Rate
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5‐fluorouracil (5‐FU) and mitomycin‐C infusion in inoperable head and neck cancer. Methods. Seventy‐six patients (86% men, 14% women), mean age 57 years, with primary inoperable head and neck cancer were treated with 70 Gy plus simultaneous intravenous chemotherapy with 5‐FU (600 mg/m2/d, days 1 to 5) and mitomycin‐C (10 mg/m2, day 5 plus 36). Results. After a mean follow‐up of 13 months, 31 patients were alive. Complete response (CR) was seen in 63%. The 1‐ and 2‐year overall survival rates were 67.7% and 39.5%, and locoregional control rates were 51.7% and 35.6%. Pretreatment hemoglobin
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.20030